ProShare Advisors
IKT icon

ProShare Advisors’s Inhibikase Therapeutics IKT Stock Holding History

ProShare Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3K Buy
15,895
+358
+2% +$641 ﹤0.01% 1883
2026
Q1 		$26.1K Buy
15,537
+4,491
+41% +$7.97K ﹤0.01% 1831
2025
Q4 		$22.6K Buy
11,046
+705
+7% +$1.12K ﹤0.01% 2017
2025
Q3 		$16.8K Sell
10,341
-2,060
-17% -$3.57K ﹤0.01% 1997
2025
Q2 		$24.2K Buy
+12,401
New +$24.3K ﹤0.01% 2058

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ProShare Advisors's IKT Position: Q2 2026 in Review

ProShare Advisors increased its Inhibikase Therapeutics (IKT) stake by 2.3% in Q2 2026, buying an estimated $641 and bringing the position to 15,895 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

ProShare Advisors first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • ProShare Advisors held 15,895 shares of Inhibikase Therapeutics worth $32.3K as of Q2 2026.
  • ProShare Advisors bought 358 Inhibikase Therapeutics shares in Q2 2026, an estimated $641.
  • Inhibikase Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1883 holding.
  • ProShare Advisors first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.